Kater, A. P., Harrup, R. A., Kipps, T. J., Eichhorst, B., Owen, C., Assouline, S. E., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Langerak, A. W., Chyla, B., Popovic, R., Jiang, Y., Millen, R., Lefebure, M., … Seymour, J. F. (2025). The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL. Blood Journal. https://doi.org/10.1182/blood.2024025525

Brown, J. R., Li, J., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Huang, R., Shi, Y., Idoine, A., Salmi, T., Cohen, A. C., & Shadman, M. (2025). ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014206

Simeone, C. A., McNulty, M. T., Gupta, Y., Genovese, G., Sampson, M. G., Sanna-Cherchi, S., Friedman, D. J., & Pollak, M. R. (2024). The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event. G3: Genes, Genomes, Genetics. https://doi.org/10.1093/g3journal/jkae290

Suhl, S., Lapolla, B., Kaminsky, A., & Geskin, L. J. (2025). Treatment of Sezary syndrome with combination romidepsin and tofacitinib: A case report. JAAD Case Reports, 55, 69–72. https://doi.org/10.1016/j.jdcr.2024.11.007

Soumerai, J. D., Barrientos, J. C., Ahn, I. E., Coombs, C. C., Gladstone, D. E., Hoffmann, M. S., Kittai, A. S., Jacobs, R. W., Lipsky, A., Patel, K., Rhodes, J. M., Skarbnik, A. P., Thompson, M. C., Ermann, D. A., Reville, P. K., Shah, H. R., Brown, J. R., & Stephens, D. M. (2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014474

Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Inzani, P. L. Z., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, M. S., Patel, M. R., Flinn, I., Gerson, J. N., Ma, S., Coombs, C. C., Cheah, C. Y., … Brown, J. R. (2024). Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. https://doi.org/10.3324/haematol.2024.285754

Lamanna, N., Tam, C. S., Woyach, J. A., Alencar, A. J., Palomba, M. L., Zinzani, P. L., Flinn, I. W., Fakhri, B., Cohen, J. B., Kontos, A., Konig, H., Ruppert, A. S., Chatterjee, A., Sizelove, R., Compte, L., Tsai, D. E., & Jurczak, W. (2024). Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. EJHaem, 5(5), 929–939. Portico. https://doi.org/10.1002/jha2.1013

Brown, J. R., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., Yimer, H. A., … Shadman, M. (2024). Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE. Blood Journal. https://doi.org/10.1182/blood.2024024667

Kim, T. O., Geris, J. M., Flanagan, J. M., Grace, R. F., Lambert, M. P., O’Farrell, C., Rose, M. J., Shimano, K. A., Niss, O., Neunert, C., Nakano, T. A., MacMath, D., Dinu, B., Kirk, S. E., Neufeld, E. J., Despotovic, J. M., Scheurer, M. E., & Grimes, A. B. (2024). Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia. Blood Advances, 8(21), 5529–5538. https://doi.org/10.1182/bloodadvances.2024012776

Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Roeker, L. E., Woyach, J. A., Cheah, C. Y. Y., Coombs, C. C., Shah, N. N., Wierda, W. G., Patel, M. R., Lamanna, N., Tsai, D. E., Nair, B. C., Wang, C., Zhao, X., Liu, D., Radtke, D., Chapman, S., Marella, N., McNeely, S. C., & Brown, J. R. (2024). Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab in Relapsed/Refractory CLL: Phase 1b BRUIN Trial. Blood Journal. https://doi.org/10.1182/blood.2024024510

Gordon, E. R., Chen, C., Adeuyan, O., Lapolla, B. A., Trager, M. H., Schreidah, C. M., Fahmy, L. M., & Geskin, L. J. (2024). Experiences of patients with cutaneous manifestations of monoclonal gammopathy of undetermined significance (MGUS): Insights from the first disease‐specific support group. JEADV Clinical Practice. Portico. https://doi.org/10.1002/jvc2.427

Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., Jacobson, S., El Dika, I., Yaqubie, A., Lopez, J., Huang, B., Tang, Y.-W., Wen, Y., Schwartz, L. H., El-Khoueiry, A. B., Knox, J. J., Rajdev, L., Bertagnolli, M. M., Meyerhardt, J. A., … Venook, A. P. (2024). CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. Cancer Research Communications, 4(3), 682–690. https://doi.org/10.1158/2767-9764.crc-22-0516

Zhou, J. J., Chen, L. N., Lehan, T., Herzberg, B., Henick, B. S., Pitman, M., Gallitano, S., & Shu, C. A. (2024). Severe scalp ulcerations and granulomata during treatment with amivantamab. Current Problems in Cancer: Case Reports, 13, 100273. https://doi.org/10.1016/j.cpccr.2023.100273

Brivio, E., Pennesi, E., Willemse, M. E., Huitema, A. D. R., Jiang, Y., van Tinteren, H. D. R., van der Velden, V. H. J., Beverloo, B. H., den Boer, M. L., Rammeloo, L. A. J., Hudson, C., Heerema, N., Kowalski, K., Zhao, H., Kuttschreuter, L., Bautista Sirvent, F. J., Bukowinski, A., Rizzari, C., Pollard, J., … Zwaan, C. M. (2024). Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of Clinical Oncology, 42(7), 821–831. https://doi.org/10.1200/jco.23.00897

Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, H., & Tedeschi, A. (2024). Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database. Haematologica. https://doi.org/10.3324/haematol.2023.283846

Gbadegesin, R., Martinelli, E., Gupta, Y., Friedman, D. J., Sampson, M. G., Pollak, M. R., & Sanna-Cherchi, S. (2024). APOL1 genotyping is incomplete without testing for the protective M1 modifier p.N264K variant. Glomerular Diseases. Portico. https://doi.org/10.1159/000537948

Lee, M. H., Song, A., & Li, J. Y. (2024). Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report. Diagnostic Pathology, 19(1). https://doi.org/10.1186/s13000-024-01446-9

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncology, 20(12), 717–726. https://doi.org/10.2217/fon-2023-0849

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B. C., Samis, J., Izquierdo, M., Titorenko, K., Li, S., & Sosothikul, D. (2023). The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Advances, 7(23), 7279–7289. https://doi.org/10.1182/bloodadvances.2023010122

Gupta, Y., Friedman, D. J., McNulty, M. T., Khan, A., Lane, B., Wang, C., Ke, J., Jin, G., Wooden, B., Knob, A. L., Lim, T. Y., Appel, G. B., Huggins, K., Liu, L., Mitrotti, A., Stangl, M. C., Bomback, A., Westland, R., Bodria, M., … Sanna-Cherchi, S. (2023). Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-43020-9

Shadman, M., Tedeschi, A., Mohseninejad, L., Yang, K., Lamanna, N., Xu, S., Cohen, A. C., Challagulla, S., Xue, M., Williams, R., O’Brien, S. M., Brown, J. R., & Tam, C. S. (2023). Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison. Blood, 142(Supplement 1), 4655–4655. https://doi.org/10.1182/blood-2023-179222

Brown, J. R., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., … Shadman, M. (2023). Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). Blood, 142(Supplement 1), 202–202. https://doi.org/10.1182/blood-2023-174289

Topping, R. P., Quill, T. A., Lamanna, N., & Sharman, J. P. (2023). Determining Clinical Practice Gaps for HCPs in Treating CLL Using CME-Based Surveys. Blood, 142(Supplement 1), 3716–3716. https://doi.org/10.1182/blood-2023-190329

Coombs, C. C., Woyach, J. A., Brown, J. R., Ghia, P., Roeker, L. E., Patel, K., Eyre, T. A., Tam, C. S., Seymour, J. F., Shah, N. N., Flinn, I. W., Cheah, C. Y., Ma, S., Rhodes, J. M., Izutsu, K., Jurczak, W., Wierda, W. G., Loubert, A., Payakachat, N., … Lamanna, N. (2023). Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study. Blood, 142(Supplement 1), 6535–6535. https://doi.org/10.1182/blood-2023-186145

Cicero, K. I., Dlamini, X., Mavengere, Y., Justman, J., Nuwagaba-Biribonwoha, H., Dlamini, M., Ngwenyama, S., Ngcamphalala, C., Low, A., Philip, N. M., El-Sadr, W. M., Sahabo, R., Abreha, T., Temesgen, S., Dlamini, S., Mahlalela, N., Chiuzan, C., Chen, Y., Pan, S. S., … Neugut, A. I. (2023). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population. Blood, 142(Supplement 1), 4767–4767. https://doi.org/10.1182/blood-2023-172435

Lipsky, A. H., Hill, B. T., Winter, A., Bachow, S. H., Viny, A. D., Rosenblat, T. L., Jurcic, J., & Lamanna, N. (2023). Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Blood, 142(Supplement 1), 3274–3274. https://doi.org/10.1182/blood-2023-189718

Kim, T. O., Geris, J. M., Grimes, A. B., Grace, R. F., Lambert, M. P., Rose, M. J., Shimano, K. A., Niss, O., Neunert, C., Nakano, T. A., Macmath, D., Dinu, B., Kirk, S. E., Despotovic, J. M., Flanagan, J. M., & Scheurer, M. E. (2023). Genetic Variants in Canonical Wnt Signaling Pathway Associated with Pediatric ITP. Blood, 142(Supplement 1), 2593–2593. https://doi.org/10.1182/blood-2023-175013

Tolu, S. S., Piorczynski, T. B., Pazos, M., Estrella, B., Huang, W., Ryu, Y. K., Cherng, H.-J. J., Pro, B., & Amengual, J. E. (2023). JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity. Blood, 142(Supplement 1), 6118–6118. https://doi.org/10.1182/blood-2023-180875

Durot, E., Roos-Weil, D., Chauchet, A., Decroocq, J., Di Blasi, R., Gastinne, T., Bensader, H., Cheminant, M., Jacquet, C., Guidez, S., Gros, F.-X., Bachy, E., Cony-Makhoul, P., Treon, S. P., Delmer, A. J., Reshef, R., Le Gouill, S., Castillo, J. J., & Houot, R. (2023). CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study. Blood, 142(Supplement 1), 616–616. https://doi.org/10.1182/blood-2023-173988

Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D. J., Campbell, P., McKay, P., Leonard, J. P., Chen, Y., Chen, J., Bannerji, R., Kapopara, A., Szanto, A., & Morschhauser, F. (2023). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up. Blood, 142(Supplement 1), 3035–3035. https://doi.org/10.1182/blood-2023-179910

Peters, D. T., Amburn, J., Tuchman, S., Lichtman, E. I., Jensen, C. E., Jain, K., Lentzsch, S., Chakraborty, R., Bhutani, D., & Rubinstein, S. M. (2023). Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance. Blood, 142(Supplement 1), 2027–2027. https://doi.org/10.1182/blood-2023-189341

Deluca, C., Beyer, M., Drew, H., Murray, J., Massey, J., Koffman, B., Battiato, K., Gribben, J. G., Lamanna, N., & Russomanno, C. (2023). The Value of Collaboration with Patient Advocacy Organizations to Enhance Initiatives Focused on Patient-Centered Care and Improve Outcomes in Chronic Lymphocytic Leukemia. Blood, 142(Supplement 1), 3715–3715. https://doi.org/10.1182/blood-2023-177959

Kim, S., Armand, J., Safonov, A., Zhang, M., Soni, R. K., Schwartz, G., McGuinness, J. E., Hibshoosh, H., Razavi, P., Kim, M., Chandarlapaty, S., & Yang, H. W. (2023). Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports, 42(11), 113198. https://doi.org/10.1016/j.celrep.2023.113198

Gordon, E., Adeuyan, O., Trager, M., Schreidah, C., Lapolla, B., Fahmy, L., Wesson, K., Magro, C., & Geskin, L. (2023). 212 An un-masking cream: discovery of T-cell dyscrasia after treatment with tapinarof. Journal of Investigative Dermatology, 143(11), S368. https://doi.org/10.1016/j.jid.2023.09.220

Malki, M. A., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., MacBeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0682

Tam, C. S., Lamanna, N., O’Brien, S. M., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Brown, J. R. (2023). Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Current Medical Research and Opinion, 39(11), 1497–1503. https://doi.org/10.1080/03007995.2023.2262378

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A., Tsai, D., & Scheliga, A. (2023). COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematology, Transfusion and Cell Therapy, 45, S161. https://doi.org/10.1016/j.htct.2023.09.359

Malick, A., Lebwohl, B., Green, P. H. R., Lagana, S., & Krishnareddy, S. (2023). S3933 Development of Celiac Disease After Immunotherapy for Psoriasis, Breast Cancer, and Renal Cell Carcinoma: A Case Series. American Journal of Gastroenterology, 118(10S), S2506–S2507. https://doi.org/10.14309/01.ajg.0000965372.95691.4d

Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., Zak, P., Wang, P.-N., Hanyok, J., Liu, L., Kamel, Y. M., Lesegretain, A., Cortes, J., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., Perl, A. E., Levis, M. J., & Erba, H. P. (2023). POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00885-6

Niehus, H., Sabile, J., Maziarz, R. T., Meyers, G., Cook, R., Gandhi, A., Saultz, J. N., Rakshe, S., Kaempf, A., Braun, T., & Migdady, Y. (2023). POSTER: MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience. Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00576-1

Konig, H., Tam, C. S., Lamanna, N., Jurczak, W., Kontos, A., Ruppert, A. S., & Tsai, D. E. (2023). POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00884-4

VanderVeer, E., Huang, S. J. T., Bruyere, H., Li, C., Ramadan, K., Villa, D., Scott, D. W., Savage, K. J., Connors, J. M., Sehn, L. H., Toze, C. L., & Gerrie, A. S. (2023). POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys. Clinical Lymphoma Myeloma and Leukemia, 23, S173. https://doi.org/10.1016/s2152-2650(23)00531-1

Masaquel, A., Li, J., Ho, R., Fox, D., Rosettie, K. L., El Moustaid, F., Qu, T., & Meng, Y. (2023). POSTER: ABCL-504 Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in the United States. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00719-x

Nastoupil, L. J., Andersen, C., Ayers, A., Wang, Y., Habermann, T. M., Chihara, D., Kahl, B. S., Link, B. K., Ayyappan, S., Cohen, J. B., Martin, P., Lossos, I. S., Casulo, C., Lin, R., Li, Z., Larson, M. A., Maurer, M. J., Huynh, L., Gao, C., … Flowers, C. R. (2023). ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy. Clinical Lymphoma Myeloma and Leukemia, 23, S442–S443. https://doi.org/10.1016/s2152-2650(23)01338-1

Karimi, Y., Ghesquieres, H., Jurczak, W., Cheah, C. Y., Clausen, M. R., Lugtenburg, P., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Stirner, M. C., Liu, Y., … Thieblemont, C. (2023). POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00718-8

Muehlenbein, C. E., Coombs, C. C., Shah, N. N., Jurczak, W., Woyach, J., Cheah, C. Y., Patel, K., Maddocks, K., Wang, Y., Wang, C., Abhyankar, S., Tsai, D. E., & Eyre, T. A. (2023). POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00883-2

Hijiya, N., Heneghan, M., Kapoor, S., Dhamal, V., Hoch, M., Descamps, L., Cardoso, A. P., & Pollard, J. (2023). POSTER: CML-532 ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00574-8

Brownlie, R. J., Kennedy, R., Wilson, E. B., Milanovic, M., Taylor, C. F., Wang, D., Davies, J. R., Owston, H., Adams, E. J., Stephenson, S., Caeser, R., Gewurz, B. E., Giannoudis, P. V., Scuoppo, C., McGonagle, D., Hodson, D. J., Tooze, R. M., Doody, G. M., Cook, G., … Klein, U. (2023). Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma. Blood Advances, 7(15), 3874–3890. https://doi.org/10.1182/bloodadvances.2022009044

Kim, W.-S., Shortt, J., Luigi Zinzani, P., Mikhaylova, N., Marin-Niebla, A., Radeski, D., Ribrag, V., Domingo Domènech, E., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY. HemaSphere, 7(S3), e6843062. https://doi.org/10.1097/01.hs9.0000971464.68430.62